MARKET

ALXN

ALXN

Alexion Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

181.25
+1.42
+0.79%
Opening 11:01 06/24 EDT
OPEN
180.35
PREV CLOSE
179.83
HIGH
182.23
LOW
180.35
VOLUME
355.84K
TURNOVER
--
52 WEEK HIGH
183.05
52 WEEK LOW
99.91
MARKET CAP
40.18B
P/E (TTM)
59.50
1D
5D
1M
3M
1Y
5Y
Alexion Pharmaceuticals Inc. stock outperforms market on strong trading day
marketwatch.com · 18h ago
Alexion Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors
marketwatch.com · 6d ago
Argenx's drug effective against muscle-weakening disease myasthenia gravis
reuters.com · 06/16 22:30
Alexion Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
marketwatch.com · 06/16 20:36
Here’s Why ClearBridge Investments Disposed its Alexion Pharmaceuticals (ALXN) Stake
ClearBridge Investments, an investment management firm, published its “Large Cap Growth Strategy” first quarter 2021 investor letter – a copy of which can be downloaded here. The ClearBridge Large Cap Growth Strategy underperformed its Russell 1000 Growth ...
Insider Monkey · 06/16 16:42
Alexion Pharmaceuticals Inc. stock outperforms competitors on strong trading day
marketwatch.com · 06/15 20:36
Alexion Wins Treasury Award for Technology Transformation, Using ICD
/PRNewswire/ -- Boston-based Alexion Pharmaceuticals, Inc. was highly commended for "Harnessing the Power of Technology" in 's Adam Smith Awards last week, using ICD, an independent portal provider of institutional  and other .
PR Newswire - PRF · 06/15 15:12
Alexion Pharmaceuticals Inc. stock remains steady Monday, underperforms market
marketwatch.com · 06/14 20:36
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALXN. Analyze the recent business situations of Alexion Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALXN stock price target is 177.36 with a high estimate of 205.00 and a low estimate of 166.00.
EPS
Institutional Holdings
Institutions: 1.04K
Institutional Holdings: 205.67M
% Owned: 92.78%
Shares Outstanding: 221.68M
TypeInstitutionsShares
Increased
233
34.07M
New
80
7.89M
Decreased
307
33.30M
Sold Out
143
11.99M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.19%
Pharmaceuticals & Medical Research
+1.32%
Key Executives
Chairman/Independent Director
David Brennan
Chief Executive Officer/Director
Ludwig Hantson
Chief Financial Officer/Executive Vice President
Aradhana Sarin
Executive Vice President/Chief Compliance Officer
Indrani Franchini
Executive Vice President/Secretary
Ellen Chiniara
Executive Vice President
Tanisha Carino
Executive Vice President
Brian Goff
Executive Vice President
John Orloff
Independent Director
Christopher Coughlin
Other
Becky Lillie
Independent Director
Deborah Dunsire
Other
Uzair Qadeer
Independent Director
Paul Friedman
Independent Director
John Mollen
Independent Director
Francois Nader
Independent Director
Judith Reinsdorf
Independent Director
Andreas Rummelt
No Data
About ALXN
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The Company’s ULTOMIRIS is a long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS is an C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses prescribed.

Webull offers kinds of Alexion Pharmaceuticals, Inc. stock information, including NASDAQ:ALXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALXN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALXN stock methods without spending real money on the virtual paper trading platform.